Danielle Abi‐Saab

Roche (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index1.4kcitations45works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(9), Alzheimer's disease research and treatments(8), Health Systems, Economic Evaluations, Quality of Life(8), Schizophrenia research and treatment(7), Treatment of Major Depression(7)

Publications45 total

Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load
Alzheimer s & Dementia·2021· 2 cited
Psychometric Properties of the Clinical Dementia Rating — Sum of Boxes and other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population
The Journal of Prevention of Alzheimer s Disease·2021· 44 citedOpen Access
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
The Journal of Prevention of Alzheimer s Disease·2021· 59 citedOpen Access
Calibration of a simplified ARIA‐E MRI severity scale suitable for clinical practice
Alzheimer s & Dementia·2020· 3 citedOpen Access
Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with gantenerumab (3931)
Neurology·2020
P33 Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab
Clinical Neurophysiology·2020
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
Alzheimer s Research & Therapy·2019· 209 citedOpen Access
P37 Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease
Clinical Neurophysiology·2019· 2 cited
DT‐01‐02: CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN‐LABEL EXTENSION STUDIES
Alzheimer s & Dementia·2019Open Access
O3‐10‐01: CORRELATION BETWEEN AMYLOID REDUCTION AND CLINICAL OUTCOMES: EXPLORATORY ANALYSES FROM THE GANTENERUMAB SCARLET ROAD AND MARGUERITE ROAD OPEN‐LABEL EXTENSION STUDIES
Alzheimer s & Dementia·2019Open Access
Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies (S9.007)
Neurology·2019· 3 cited
MOESM3 of Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
Figshare·2019Open Access
O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION
Alzheimer s & Dementia·2018· 8 cited
O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY
Alzheimer s & Dementia·2018· 11 cited
O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES
Alzheimer s & Dementia·2018· 3 cited
O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION
Alzheimer s & Dementia·2018· 6 citedOpen Access
Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005)
Neurology·2018· 4 cited
[P1–045]: THE EFFECT OF 6 MONTHS’ DOSING ON THE RATE OF AMYLOID‐RELATED IMAGING ABNORMALITIES (ARIA) IN THE MARGUERITE ROAD STUDY
Alzheimer s & Dementia·2017· 9 cited
[P1–050]: CORRELATION BETWEEN BASELINE VASCULAR PATHOLOGY/RISK FACTORS AND PROGRESSION OF ALZHEIMER'S DISEASE IN A PRODROMAL POPULATION
Alzheimer s & Dementia·2017
[P3–015]: THE IMPACT OF ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOA) ON ALZHEIMER's DISEASE CLINICAL TRIAL DATA QUALITY
Alzheimer s & Dementia·2017· 2 cited
page 1 of 3Next →

Frequent Co-authors

Paul Delmar(20), Rachelle S. Doody(17), Paulo Fontoura(15), Gregory Klein(14), Nicola Voyle(14), Deepak Cyril D’Souza(13), Monika Baudler(13), Mirjana Andjelković(12), Carsten Hofmann(11), John H. Krystal(11), Smiljana Ristič(9), Geoffrey A. Kerchner(9), Roberto Gil(8), Anissa Abi‐Dargham(7), John Krystal(6), Dennis S. Charney(6), E. Zuzarte(6), L. Karper(6), Dennis S. Charney(5), Sunita Rehal(5)